Fas ligand as a tool for immunosuppression and generation of immune tolerance

Stem Cells

Volumn 22, Issue 6, 2004, Pages 908-924

  Bohana Kashtan, Osnat ^a   Civin, Curt I ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Allogeneic; Dendritic cells; Fas ligand(FasL); gld; Immune privilege; lpr; Tolerance

Indexed keywords

FAS LIGAND;

ALLOGRAFT; AUTOIMMUNITY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; SHORT SURVEY;

EID: 8644250720     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.22-6-908     Document Type: Short Survey

References (205)

1. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245-254.
2. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000;407:796-801.
3. Siegel RM, Chan FK, Chun HJ et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469-474.
4. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003;4:410-415.
5. Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
6. Hahne M, Peitsch MC, Irmler M et al. Characterization of the non-functional Fas ligand of gld mice. Int Immunol 1995;7:1381-1386.
7. Wu J, Wilson J, He J et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-1113.
8. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 1998;43:2-8.
9. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003;15:325-331.
10. Mogil RJ, Radvanyi L, Gonzalez-Quintial R et al. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 1995;7:1451-1458.
11. Renno T, Hahne M, Tschopp J et al. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med 1996;183:431-437.
12. Adachi M, Suematsu S, Suda T et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996;93:2131-2136.
13. Bonfoco E, Stuart PM, Brunner T et al. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 1998;9:711-720.
14. Pinkoski MJ, Droin NM, Lin T et al. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion. Proc Natl Acad Sci U S A 2002;99:16174-16179.
15. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003;193:70-81.
16. 2+-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
17. Kojima H, Shinohara N, Hanaoka S et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994;:357-364.
18. Walsh CM, Glass AA, Chiu V et al. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol 1994;153:2506-2514.
19. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-1238.
20. Eischen CM, Leibson PJ. Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis. Res Immunol 1997;148:164-169.
21. Hanabuchi S, Koyanagi M, Kawasaki A et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 1994;91:4930-4934.
22. + cytotoxic T cells. Proc Natl Acad Sci U S A 1994;91:4185-4189.
23. + T cell-mediated cytotoxicity. J Immunol 1994;152:1127-1133.
24. + T cells. Nature 1995;376:181-184.
25. Wang H, Shlomchik MJ. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J Exp Med 1999;190:639-649.
26. Melamed D, Miri E, Leider N et al. Unexpected autoantibody production in membrane Ig-mu-deficient/lpr mice. J Immunol 2000;165:4353-4358.
27. Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
28. Chinnaiyan AM, O'Rourke K, Tewari M et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
29. Boldin MP, Varfolomeev EE, Pancer Z et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-7798.
30. Kischkel FC, Hellbardt S, Behrmann I et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-5588.
31. Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
32. Boldin MP, Goncharov TM, Goltsev YV et al. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996;85:803-815.
33. Vincenz C, Dixit VM. Fas-associated death domain protein interleukin-1 beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. J Biol Chem 1997;272:6578-6583.
34. Wang J, Chun HJ, Wong W et al. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci U S A 2001;98:13884-13888.
35. Kischkel FC, Lawrence DA, Tinel A et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001;276:46639-46646.
36. Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-1687.
37. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003;15:185-193.
38. Li H, Zhu H, Xu CJ et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
39. Luo X, Budihardjo I, Zou H et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-490.
40. Eskes R, Desagher S, Antonsson B et al. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000;20:929-935.
41. Wei MC, Lindsten T, Mootha VK et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000;14:2060-2071.
42. Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
43. Zou H, Li Y, Liu X et al. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-11556.
44. Yin XM, Wang K, Gross A et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400:886-891.
45. Wei MC, Zong WX, Cheng EH et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-730.
46. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003;15:983-992.
47. Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-1783.
48. Tanaka M, Suda T, Takahashi T et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 1995;14:1129-1135.
49. Powell WC, Fingleton B, Wilson CL et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999;9:1441-1447.
50. Aoki K, Kurooka M, Chen JJ et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001;2:333-337.
51. Kanda Y, Chiba S, Tanaka Y et al. Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Leuk Lymphoma 1999;34:625-628.
52. Mizutani Y, Hongo F, Sato N et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001;92:287-293.
53. Osorio LM, Aguilar-Santelises M, De Santiago A et al. Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol 2001;66:342-346.
54. Frankel B, Longo SL, Canute GW. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion. J Neurooncol 2000;48:21-26.
55. Song E, Chen J, Ouyang N et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001;85:1047-1054.
56. Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-3813.
57. Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
58. Sabelko-Downes KA, Cross AH, Russell JH. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 1999;189:1195-1205.
59. Suvannavejh GC, Dal Canto MC, Matis LA et al. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2000;105:223-231.
60. Gochuico BR, Miranda KM, Hessel EM et al. Airway epithelial Fas ligand expression: potential role in modulating bronchial inflammation. Am J Physiol 1998;274:L444-449.
61. Hunt JS, Vassmer D, Ferguson TA et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997;158:4122-4128.
62. Ferguson TA, Green DR, Griffith TS. Cell death and immune privilege. Int Rev Immunol 2002;21:153-172.
63. Hu MS, Schwartzman JD, Yeaman GR et al. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect Immunol 1999;67:928-935.
64. Stuart PM, Griffith TS, Usui N et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402.
65. O'Connell J, O'Sullivan GC, Collins JK et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082.
66. Houston A, Bennett MW, O'Sullivan GC et al. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer 2003;89:1345-1351.
67. Houston A, Waldron-Lynch FD, Bennett MW et al. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer 2003;107:209-214.
68. Nozoe T, Yasuda M, Honda M et al. Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 2003;65:83-88.
69. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-1366.
70. Chen YL, Chen SH, Wang JY et al. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003;171:1183-1191.
71. Gastman BR, Atarshi Y, Reichert TE et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-5364.
72. Hoffmann TK, Dworacki G, Tsukihiro T et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8:2553-2562.
73. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996;2:1361-1366.
74. Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-1012.
75. Viard-Leveugle I, Veyrenc S, French LE et al. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003;201:268-277.
76. Villunger A, Egle A, Marschitz I et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997;90:12-20.
77. Hammer A, Hartmann M, Sedlmayr P et al. Expression of functional Fas ligand in choriocarcinoma. Am J Reprod Immunol 2002;48:226-234.
78. Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-5675.
79. Arai H, Gordon D, Nabel EG et al. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997;94:13862-13867.
80. Seino K, Kayagaki N, Fukao K et al. Rejection of Fas ligand-expressing grafts. Transplant Proc 1997;29:1092-1093.
81. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol 2002;10:101-108.
82. Libby P, Pober JS. Chronic rejection. Immunity 2001;14:387-397.
83. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124.
84. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-1751.
85. Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology 2003;185:229-240.
86. Griffith TS, Yu X, Herndon JM et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996;5:7-16.
87. Kawashima H, Yamagami S, Tsuru T et al. Anterior chamber inoculation of splenocytes without Fas/Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation. Eur J Immunol 1997;27:2490-2494.
88. Hill LL, Shreedhar VK, Kripke ML et al. A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med 1999;189:1285-1294.
89. Freire-de-Lima CG, Nascimento DO, Soares MB et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 2000;403:199-203.
90. Steinman RM, Turley S, Mellman I et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-416.
91. Deng C, Goluszko E, Christadoss P. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance. J Immunol 2001;166:3458-3467.
92. Ferguson TA, Stuart PM, Herndon JM et al. Apoptosis, tolerance, and regulatory T cells: old wine, new wineskins. Immunol Rev 2003;193:111-123.
93. Chiffoleau E, Walsh PT, Turka L. Apoptosis and transplantation tolerance. Immunol Rev 2003;193:124-145.
94. Gao Y, Herndon JM, Zhang H et al. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med 1998;188:887-896.
95. Swenson KM, Ke B, Wang T et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998;65:155-160.
96. Ke B, Coito AJ, Kato H et al. Fas ligand gene transfer prolongs rat renal allograft survival and down-regulates anti-apoptotic Bag-1 in parallel with enhanced Th2-type cytokine expression. Transplantation 2000;69:1690-1694.
97. Takeuchi T, Ueki T, Nishimatsu H et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999;162:518-522.
98. Askenasy N, Yolcu ES, Wang Z et al. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 2003;107:1525-1531.
99. Min WP, Gorczynski R, Huang XY et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000;164:161-167.
100. Sata M, Walsh K. TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998;4:415-420.
101. Sata M, Luo Z, Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 2001;166:6964-6971.
102. Sata M, Perlman H, Muruve DA et al. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA 1998;95:1213-1217.
103. Luo Z, Sata M, Nguyen T et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 1999;99:1776-1779.
104. Yang J, Jones SP, Suhara T et al. Endothelial cell overexpression of Fas ligand attenuates ischemia-reperfusion injury in the heart. J Biol Chem 2003;278:15185-15191.
105. Li XK, Okuyama T, Tamura A et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998;66:1416-1423.
106. Schmid RA, Stammberger U, Hillinger S et al. Fas ligand gene transfer combined with low dose cyclosporine A reduces acute lung allograft rejection. Transpl Int 2000;13(suppl 1):S324-S328.
107. Saitoh A, Kawanabe T, Weidong H et al. Selective upregulation of fibroblast Fas ligand expression, and prolongation of Fas/Fas ligand-mediated skin allograft survival, by retinoic acid: the skin as a retinoide-inducible immune privilege site. J Invest Dermatol 2000;115:154-161.
108. Tourneur L, Malassagne B, Batteux F et al. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J Immunol 2001;167:1338-1346.
109. Allison J, Georgiou HM, Strasser A et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U S A 1997;94:3943-3947.
110. Kang SM, Schneider DB, Lin Z et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-743.
111. D'Alessio A, Riccioli A, Lauretti P et al. Testicular FasL is expressed by sperm cells. Proc Natl Acad Sci U S A 2001;98:3316-3321.
112. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997;46:317-322.
113. Takeda Y, Gotoh M, Dono K et al. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabetologia 1998;41:315-321.
114. Lau HT, Yu M, Fontana A et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-112.
115. Turvey SE, Gonzalez-Nicolini V, Kingsley CI et al. Fas ligand-transfected myoblasts and islet cell transplantation. Transplantation 2000;69:1972-1976.
116. Kang SM, Hoffmann A, Le D et al. Immune response and myoblasts that express Fas ligand. Science 1997;278:1322-1324.
117. Yolcu ES, Askenasy N, Singh NP et al. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002;17:795-808.
118. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-674.
119. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-3204.
120. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies: results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994;13:597-611.
121. Filipovich AH, Vallera D, McGlave P et al. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: the correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation 1990;50:410-415.
122. Soiffer RJ, Murray C, Mauch P et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 1992;10:1191-1200.
123. Kawanishi Y, Passweg J, Drobyski WR et al. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplant 1997;19:1069-1077.
124. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-3955.
125. Bachar-Lustig E,Rachamim N, Li HW et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-1273.
126. Whartenby KA, Straley EE, Kim H et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002;100:3147-3154.
127. Sayegh MH, Fine NA, Smith JL et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991;114:954-955.
128. Helg C, Chapuis B, Bolle JF et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 1994;58:1420-1422.
129. Sellers MT, Deierhoi MH, Curtis JJ et al. Tolerance in renal transplantation after allogeneic bone marrow transplantation: 6-year follow-up. Transplantation 2001;71:1681-1683.
130. George JF, Sweeney SD, Kirklin JK et al. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med 1998;4:333-335.
131. Goldstein DR, Thomas JM, Kirklin JK et al. Indefinite allograft survival mediated by donor bone marrow is dependent on the presence of a functional CD95 (Fas) gene in recipients. J Heart Lung Transplant 2001;20:1132-1135.
132. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2002;2:195-204.
133. Batteux F, Lores P, Bucchini D et al. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis. J Immunol 2000;164:1681-1688.
134. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788-794.
135. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000;6:88-91.
136. Zhu B, Luo L, Chen Y et al. Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002;169:1561-1569.
137. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
138. Holmdahl R, Bockermann R, Backlund J et al. The molecular pathogenesis of collagen-induced arthritis in mice: a model for rheumatoid arthritis. Ageing Res Rev 2002;1:135-147.
139. Zhang HG, Yang P, Xie J et al. Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice. J Immunol 2002;168:4164-4172.
140. Hsu HC, Zhang HG, Song GG et al. Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection. Arthritis Rheum 2001;44:2146-2159.
141. Nicolle MW. Myasthenia gravis. Neurologist 2002;8:2-21.
142. Wu JM, Wu B, Guarnieri F et al. Targeting antigen-specific T cells by genetically engineered antigen presenting cells: a strategy for specific immunotherapy of autoimmune disease. J Neuroimmunol 2000;106:145-153.
143. Wu B, Wu JM, Miagkov A et al. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J Immunol 2001;166:4773-4779.
144. Drachman DB, Wu JM, Miagkov A et al. Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the "guided missile" strategy. Ann N Y Acad Sci 2003;998:520-532.
145. Borchers AT, Naguwa SM, Keen CL et al. Immunopathogenesis of Sjogren's syndrome. Clin Rev Allergy Immunol 2003;25:89-104.
146. Fleck M, Kern ER, Zhou T et al. Murine cytomegalovirus induces a Sjogren's syndrome-like disease in C57B1/6-lpr/lpr mice. Arthritis Rheum 1998;41:2175-2184.
147. Fleck M, Zhang HG, Kern ER et al. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum 2001;44:964-973.
148. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106:259-262.
149. Moser M. Dendritic cells in immunity and tolerance: do they display opposite functions? Immunity 2003;19:5-8.
150. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-449.
151. Steinman RM, Hawiger D, Liu K et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003;987:15-25.
152. Mahnke K, Schmitt E, Bonifay L et al. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002;80:477-483.
153. Mahnke K, Knops J, Ink AH. Induction of tolerogenic DCs: 'you are what you eat.' Trends Immunol 2003;24:646-651.
154. Gad M, Caisson MH, Pedersen AE. Dendritic cells in peripheral tolerance and immunity. APMIS 2003;111:766-775.
155. + T cells. J Exp Med 1997;186:239-245.
156. Hawiger D, Indaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-779.
157. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood 2002;100:174-177.
158. Wakkach A, Fournier N, Brun V et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605-617.
159. Munn DH, Sharma MD, Lee JR et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-1870.
160. Munn DH. Tolerogenic antigen-presenting cells. Ann NY Acad Sci 2002;961:343-345.
161. Chang CC, Ciubotariu R, Manavalan JS et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002;3:237-243.
162. Manavalan JS, Rossi PC, Vlad G et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003;11:245-258.
163. Gorczynski RM, Yu K, Clark D. Receptor engagement on cells expressing a ligand for the tolerance-inducing molecule OX2 induces an immunoregulatory population that inhibits alloreactivity in vitro and in vivo. J Immunol 2000;165:4854-4860.
164. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002;73:S19-S22.
165. Morel PA, Feili-Hariri M, Coates PT et al. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol 2003;133:1-10.
166. Ichim TE, Zhong R, Min WP. Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl Immunol 2003;11:295-306.
167. Matsue H, Matsue K, Walters M et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999;5:930-937.
168. Matsue H, Matsue K, Kusuhara M et al. Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 2001;98:3465-3472.
169. Hoves S, Krause SW, Halbritter D et al. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol 2003;170:5406-5413.
170. Willems F, Amraoui Z, Vanderheyde N et al. Expression of C-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 2000;95:3478-3482.
171. Lundqvist A, Nagata T, Kiessling R et al. Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother 2002;51:139-144.
172. + T cells from D011.10 mice. Eur J Immunol 2002;32:1035-1043.
173. + T cells by Fas ligand (FasL/CD95L)-expressing killer-dendritic cells. Immunobiology 2004;208:463-475.
174. Zhang HG, Su X, Liu D et al. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 1999;162:1423-1430.
175. Kosiewicz MM, Krishnan A, Worthington MT et al. B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo. Eur J Immunol 2002;32:1679-1687.
176. Georgantas RW 3rd, Leong KW, August JT. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum Gene Ther 2000;11:851-858.
177. Buonocore S, Van Meirvenne S, Demoor FX et al. Dendritic cells transduced with viral interleukin 10 or Fas ligand: no evidence for induction of allotolerance in vivo. Transplantation 2002;73:S27-S30.
178. Buonocore S, Paulart F, Le Moine A et al. Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood 2003;101:1469-1476.
179. Ogasawara J, Watanabe-Fukunaga R, AdachiM et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
180. Rensing-Ehl A, Frei K, Flury R et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-2258.
181. Morelli AE, Larregina AT, Smith-Arica J et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999;80(Pt 3):571-583.
182. Okuyama T, Fujino M, Li XK et al. Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system. Gene Ther 1998;5:1047-1053.
183. Rubinchik S, Ding R, Qiu AJ et al. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000;7:875-885.
184. Smith RC, Machluf M, Bromley P et al. Spatial and temporal control of transgene expression through ultrasound-mediated induction of the heat shock protein 70B promoter in vivo. Hum Gene Ther 2002;13:697-706.
185. Sano Y, Yamada J, Ishino Y et al. Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege. Exp Eye Res 2002;75:475-483.
186. Gregory MS, Repp AC, Holhbaum AM et al. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol 2002;169:2727-2735.
187. Cheng J, Liu C, Yang P et al. Increased lymphocyte apoptosis in Fas ligand transgenic mice. J Immunol 1997;159:674-684.
188. Perlman H, Pagliari LJ, Georganas C et al. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 1999;190:1679-1688.
189. Wang J, Lobito AA, Shen F et al. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur J Immunol 2000;30:155-163.
190. Hasebe H, Sato K, Yanagie H et al. Bcl-2, Bcl-xL and c-FLIP(L) potentially regulate the susceptibility of human peripheral blood monocyte-derived dendritic cells to cell death at different developmental stages. Biomed Pharmacother 2002;56:144-151.
191. Abreu-Martin MT, Vidrich A, Lynch DH et al. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol 1995;155:4147-4154.
192. Miwa K, Asano M, Horai R et al. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998;4:1287-1292.
193. Schaub FJ, Han DK, Liles WC et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000;6:790-796.
194. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191:1209-1220.
195. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID): III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 1992;22:165-173.
196. Knisely TL, Hosoi J, Nazareno R et al. The presence of biologically significant concentrations of glucocorticoids but little or no cortisol binding globulin within aqueous humor: relevance to immune privilege in the anterior chamber of the eye. Invest Ophthalmol Vis Sci 1994;35:3711-3723.
197. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 1994:153:1080-1086.
198. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998;282:1714-1717.
199. Yamaoka-Tojo M, Yamaguchi S, Nitobe J et al. Dual response to Fas ligation in human endothelial cells: apoptosis and induction of chemokines, interleukin-8 and monocyte chemoattractant protein-1. Coron Artery Dis 2003;14:89-94.
200. Schneider P, Holler N, Bodmer JL et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-1213.
201. Shudo K, Kinoshita K, Imamura R et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001;31:2504-2511.
202. Seino K, Kayagaki N, Tsukada N et al. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts. Transplantation 1997;64:1050-1054.
203. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
204. Coates PT, Colvin BL, Kaneko K et al. Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation 2003;75:32S-36S.
205. Schroeder RA, Marroquin CE, Kuo PC. Tolerance and the "Holy Grail" of transplantation. J Surg Res 2003;111:109-119.